CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Theseus
Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies, today
announced that the Company will present a poster highlighting the
characterization of potent and selective next-generation EGFR
inhibitors at the American Association for Cancer Research (AACR)
2022 Annual Meeting, being held April 8-13,
2022 in New Orleans,
Louisiana.
Presentation details:
Abstract Title:
Discovery of potent and selective next-generation EGFR inhibitors
with activity against single, double, and triple mutant EGFR
variants including T790M and C797S
Abstract Number: 3342
Presenter: Wei-Sheng Huang, Ph.D., Vice President of
Chemistry
Session Date and Time: Tuesday, April 12th,
1:30pm-5pm CT
The presentation will detail the characterization of compounds
that potently inhibit the kinase activity, both in vitro and
in vivo, of single, double, and triple mutant EGFR variants
including T790M and C797S, with selectivity over wild-type EGFR and
the ability to penetrate the central nervous system. These variants
comprise all major classes of EGFR activating and resistance
mutations that contribute to later-line clonal heterogeneity in
patients who have been failed by current approved therapies.
EGFR activating mutations are observed in 10-50 percent of
non-small cell lung cancer (NSCLC) patients and are initially
sensitive to first, second, and third generation EGFR inhibitors.
However, on-target resistance is observed in a substantial
percentage of patients, with T790M and C797S mutations observed
most frequently.
About Theseus Pharmaceuticals, Inc.
Theseus is a
clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies. Theseus is
working to outsmart cancer resistance by developing pan-variant
tyrosine kinase inhibitors (TKIs) to target all known classes of
cancer-causing and resistance mutations that lead to variants in a
particular protein in a given type of cancer. Theseus' lead product
candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors
(GIST), whose cancer has developed resistance to earlier lines of
kinase inhibitor therapy. Theseus is also developing a
fourth-generation, selective epidermal growth factor receptor
(EGFR) inhibitor for C797S-mediated resistance to first- or
later-line osimertinib treatment in patients with non-small cell
lung cancer (NSCLC). For more information,
visit www.theseusrx.com.
Cautionary Statement Regarding Forward Looking
Statements
Certain statements included in this press release
are not historical facts but are forward-looking statements for
purposes of the safe harbor provisions under the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as "believe,"
"may," "will," "estimate," "continue," "anticipate," "intend,"
"expect," "should," "would," "plan," "predict," "potential,"
"seem," "seek," "future," "outlook," and similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters, but the absence of these words
does not mean that a statement is not forward-looking. These
forward-looking statements include, but are not limited to,
statements regarding Theseus' strategy, future operations,
prospects and plans, the structure and timing of its planned and
ongoing clinical trials and future registrational trials, expected
milestones, market opportunity and sizing and objectives of
management, including in relation to THE-630 and the Phase 1/2 does
escalation and expansion clinical trial and its EGFR and other
programs.
Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, such as those described from time to time in the reports
Theseus files with the Securities and Exchange Commission (SEC),
including Theseus' Form 10-Q for the quarter ended September
30, 2021 filed with the SEC on November 15, 2021.
However, new risk factors and uncertainties may emerge from time to
time, and it is not possible to predict all risk factors and
uncertainties. Accordingly, readers are cautioned not to place
undue reliance on these forward-looking statements. Any
forward-looking statements contained in this press release are
based on the current expectations of Theseus' management team and
speak only as of the date hereof, and Theseus specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Media Contact
Amy Jobe,
Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
Investor Contact
Christen
Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-present-preclinical-data-characterizing-next-generation-epidermal-growth-factor-receptor-egfr-inhibitors-at-the-2022-american-association-for-cancer-research-aacr-annual-meeting-301498441.html
SOURCE Theseus Pharmaceuticals